Business Context and Reporting Period
This Form 8-K Current Report from Black Diamond Therapeutics, Inc. (BDTX) covers events occurring on September 15, 2023, and September 16, 2023. The filing details a significant leadership transition involving the departure of the Chief Executive Officer and the appointment of a successor.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. This report focuses exclusively on executive compensation and personnel changes.
- CEO Base Salary (New): $620,000 annually.
- CEO Performance Bonus (New): Up to 55% of base salary.
- CEO Equity Grant (New): Stock options to purchase 1,000,000 shares of common stock.
- CEO Severance (New): 12 months of base salary plus target bonus upon termination without Cause or for Good Reason.
Material Changes
The primary material change is the replacement of the Company's top executive:
- Departure: David M. Epstein, Ph.D., separated as President and CEO effective September 15, 2023. He will remain on the Board of Directors until the 2024 annual meeting without additional compensation, though his existing equity awards will continue to vest.
- Appointment: Mark A. Velleca, M.D., Ph.D., was appointed President and CEO effective September 16, 2023. He previously served as Chair of the Board and will continue in that role.
- Governance Change: Samarth Kulkarni, Ph.D., was appointed as the new Lead Independent Director.
Outlook, Risks, and Unusual Items
The filing does not contain forward-looking guidance, financial outlook, or specific risk factors beyond the standard implications of executive turnover. The appointment of Dr. Velleca, who has extensive experience in oncology and biopharmaceutical leadership (including prior CEO roles at G1 Therapeutics and StrideBio), suggests a strategic shift in operational leadership. The Employment Agreement includes standard severance protections and accelerated vesting provisions for the new CEO.
Investor Verification Checklist
- Verify the terms of the Separation Agreement with Dr. Epstein (Exhibit 10.1) to confirm total severance costs.
- Review the full Employment Agreement with Dr. Velleca (Exhibit 10.2) for specific definitions of "Cause," "Good Reason," and "Change in Control."
- Assess the impact of the 1,000,000 share option grant on existing shareholder dilution.
- Confirm the timeline for the 2024 annual meeting regarding Dr. Epstein's continued Board service.